Adeona Pharmaceuticals Common Stock News - AEN

Adeona Becomes Synthetic Biologics, Inc.

Adeona Becomes Synthetic Biologics, Inc. -- New Name Reflects Biotechnology Company Focus on the Emerging Field of Synthetic Biologics -- -- New...

- Current report filing (8-K)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or...

- Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Adeona CEO to Present at the Harvard Investors Group Forum

Adeona CEO to Present at the Harvard Investors Group Forum PR Newswire ANN ARBOR, Mich., Feb. 9, 2012 ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/...

- Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to...

- Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic...

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Adeona Pharmaceuticals Common Stock (AEN)

Get an advanced news scanner tailored to your needs by ADVFN

AEN News

Adeona Becomes Synthetic Biologics, Inc.

- Current report filing (8-K)

- Initial Statement of Beneficial Ownership (3)

Adeona CEO to Present at the Harvard Investors Group Forum

- Initial Statement of Beneficial Ownership (3)

- Current report filing (8-K)

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

- Initial Statement of Beneficial Ownership (3)

- Statement of Changes in Beneficial Ownership (4)

- Current report filing (8-K)

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

- Amended Current report filing (8-K/A)

- Amended Statement of Ownership (SC 13G/A)

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

- Proxy Statement (definitive) (DEF 14A)

AEN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Adeona Pharmaceuticals Common Stock (AEN) News

Adeona Pharmaceuticals Common Stock (AEN)

Get an advanced news scanner tailored to your needs by ADVFN

AEN News

Adeona Becomes Synthetic Biologics, Inc.

- Current report filing (8-K)

- Initial Statement of Beneficial Ownership (3)

Adeona CEO to Present at the Harvard Investors Group Forum

- Initial Statement of Beneficial Ownership (3)

- Current report filing (8-K)

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

- Initial Statement of Beneficial Ownership (3)

- Statement of Changes in Beneficial Ownership (4)

- Current report filing (8-K)

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

- Amended Current report filing (8-K/A)

- Amended Statement of Ownership (SC 13G/A)

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

- Proxy Statement (definitive) (DEF 14A)

AEN Discussion

Your Recent History

Company

Business

Popular

Get The App